BI 3034701 is Boehringer Ingelheim's potential first-in-class GLP-1/GIP/NPY2 triple receptor agonist for the treatment of obesity, discovered through the long-running Boehringer-Gubra Biopharmaceutical peptide discovery collaboration. Boehringer initiated the Phase 2 clinical trial in July 2026 to test the drug in adults with obesity and overweight.
The differentiation angle is the NPY2 receptor arm. Retatrutide (Eli Lilly) and ribupatide (Hengrui-Kailera) are GIP/GLP-1/glucagon triple agonists that engage the incretin axis plus glucagon-mediated energy expenditure. BI 3034701 engages GLP-1 and GIP through the same incretin biology but substitutes NPY2 receptor agonism for the glucagon arm. NPY2 is a receptor for peptide YY (PYY, secreted by intestinal L cells) that acts on the hypothalamus to reduce food intake — the mechanism that historically motivated PYY-mimetic obesity development at Merck, Novo Nordisk, and academic groups.
BI 3034701 joins Boehringer's broader obesity pipeline anchored on survodutide (dual GLP-1/glucagon agonist in Phase 3 MASH under the Zealand Pharma partnership, with the Phase 3 SYNCHRONIZE readout expected late 2026). Boehringer is positioned as the credible third or fourth-place obesity challenger behind Eli Lilly, Novo Nordisk, and Roche. Phase 2 readout timing for BI 3034701 has not been publicly disclosed as of September 2026. Stories here cover clinical readouts, mechanism work, and the broader triple-agonist competitive landscape. See [[boehringer-ingelheim]], [[survodutide]], and [[retatrutide]] for adjacent threads.
Boehringer Ingelheim continues enrollment through September 2026 in the Phase 2 clinical trial of BI 3034701 (a potential first-in-class GLP-1/GIP/NPY2 triple receptor agonist), which the company initiated in July 2026 as part of the expanded obesity pipeline anchored on survodutide (dual GLP-1/glucagon agonist, in Phase 3 MASH with Zealand Pharma partnership). BI 3034701 was discovered via the Boehringer-Gubra Biopharmaceutical peptide discovery collaboration and is designed to engage the NPY2 receptor alongside GLP-1 and GIP receptors — a differentiated triple-target mechanism versus Eli Lilly's retatrutide (GIP/GLP-1/glucagon) and Hengrui's ribupatide (GIP/GLP-1/glucagon). The NPY2 receptor pathway is involved in central appetite regulation and has been targeted historically by hormones including PYY(3-36); Boehringer positions BI 3034701 as engaging appetite regulation through a complementary mechanism to the incretin axis. Phase 2 readout timing has not been publicly disclosed. Boehringer Ingelheim's overall obesity pipeline positions the company as a distant third-place challenger to Eli Lilly and Novo Nordisk with survodutide, BI 3034701, and the emerging GLP-1/glucagon dual agonist program.
Boehringer Ingelheim announced Thursday July 16, 2026 the start of a Phase 2 clinical trial evaluating BI 3034701, its investigational triple GLP-1/GIP/NPY2 receptor agonist peptide, in patients with obesity and overweight. BI 3034701 is a potential first-in-class triple agonist designed to activate three complementary biological pathways: GLP-1 and GIP receptors reduce appetite and regulate metabolism, and the neuropeptide Y2 (NPY2) receptor modulates central hunger signaling. Phase 1 studies previously showed a generally favorable safety and tolerability profile that supported advancing the program. BI 3034701 is based on Gubra-discovered technology and licensed to Boehringer Ingelheim, which is responsible for global clinical development and commercialization. The program adds a distinct third target to the emerging next-generation obesity landscape: Eli Lilly's retatrutide (GLP-1/GIP/glucagon triple agonist in TRIUMPH Phase 3), Novo Nordisk's UBT251 (GLP-1/GIP/glucagon triple in Phase 1/2a), and Boehringer's dual glucagon/GLP-1 survodutide (Phase 3, 16.6% weight loss in obesity). The NPY2 receptor target is novel to the class and could carry a distinct safety and tolerability profile alongside the incretin-plus-incretin backbone.
Boehringer Ingelheim disclosed alongside the survodutide topline that BI 3034701, a first-in-class triple GLP-1/GIP/NPY2 receptor agonist peptide, will enter Phase 2 in mid-2026. The compound completed a randomized placebo-controlled Phase 1 study in healthy volunteers and people with overweight/obesity that demonstrated favorable safety and tolerability and encouraging weight loss. BI 3034701 was developed in collaboration with Gubra, with Boehringer responsible for further development and global commercialization. The novel NPY2 component targets satiety pathways complementary to incretin agonism — a meaningful mechanistic differentiation in the next-gen obesity pipeline.